Ginkgo Bioworks Holdings, Inc.
DNA
$7.71
-$0.14-1.78%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 35.52% | 42.83% | 47.86% | 64.89% | 44.71% |
| Total Depreciation and Amortization | -17.22% | -10.60% | -9.96% | -28.33% | -24.33% |
| Total Amortization of Deferred Charges | -3.19% | 1.11% | 36.84% | -- | 452.94% |
| Total Other Non-Cash Items | -42.16% | -51.74% | -58.50% | -71.07% | -52.40% |
| Change in Net Operating Assets | 51.77% | 56.09% | 72.67% | -370.18% | -437.86% |
| Cash from Operations | 41.02% | 46.47% | 50.50% | 22.07% | 4.19% |
| Capital Expenditure | 96.89% | 87.74% | 59.12% | 12.29% | -126.05% |
| Sale of Property, Plant, and Equipment | -11.42% | -11.42% | -97.18% | -56.86% | -85.37% |
| Cash Acquisitions | -- | -- | 100.00% | 100.00% | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 90.82% | -4,711.39% | -11,730.29% | -44,630.95% | -13,506.80% |
| Cash from Investing | 92.58% | -286.09% | -263.66% | -221.17% | -239.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 79.51% | 60.54% | 47.43% | 37.95% | 36.07% |
| Issuance of Common Stock | 138,964.29% | 23,077.38% | 10,427.55% | -100.00% | -90.73% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -339.34% | -44.71% | 71.16% | 73.68% | 85.00% |
| Cash from Financing | 1,731.52% | 1,122.14% | 534.96% | 51.78% | 65.30% |
| Foreign Exchange rate Adjustments | 96.00% | 171.53% | 364.15% | 157.14% | 93.05% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 68.65% | -2.48% | -16.51% | -32.31% | -43.17% |